A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes After Hypomethylating Agent-Failure

Trial Profile

A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes After Hypomethylating Agent-Failure

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Venetoclax (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 09 Oct 2017 Trial focus has been changed from TU, PK, AR to PK and AR. Due to this official title, primary endpoint and purpose also got updated.
    • 09 Oct 2017 Planned number of patients changed from 66 to 68.
    • 09 Oct 2017 Planned End Date changed from 10 May 2020 to 4 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top